THE APEX TIMES
Gottlieb tells Face the Nation he says Trump FDA nominee Heidi Overton could be a strong candidate
Former FDA Commissioner Dr. Scott Gottlieb said on CBS News that President Donald Trump’s pick for FDA leadership, Dr. Heidi Overton, has a “deep policy background” that could make her well-suited for the role.
President Donald Trump’s proposed FDA leadership has drawn early reactions from senior public-health policy figures, including former Food and Drug Administration Commissioner Dr. Scott Gottlieb, who told CBS News that Dr. Heidi Overton “could be a strong candidate” to lead the agency.
Appearing on “Face the Nation with Margaret Brennan,” Gottlieb said Overton’s potential strength comes from what he described as her “deep policy background,” pointing to expertise he said would matter for running a regulator that oversees drugs, biologics, vaccines, and other products.
CBS News reported Gottlieb’s remarks in connection with Trump’s FDA pick. Gottlieb is not part of the nomination process described in the segment, but his comments reflect the kind of policy and technical qualifications stakeholders often weigh when an FDA commissioner role is under consideration.
The former FDA commissioner also characterized his own experience and current institutional roles in the segment. He is described by CBS as serving on the boards of Pfizer and United Healthcare, positions he has cited as part of his ongoing engagement with health-related industries.
For FDA leadership, the practical stakes include how the agency prioritizes regulatory approaches, manages oversight of medical products and clinical evidence, and sets enforcement and compliance priorities across regulated categories. Gottlieb’s remarks focused specifically on policy depth as a driver of fit for the job rather than on any particular enforcement action or program change.
No additional details about an official nomination timeline, Senate review schedule, or specific platform proposals were included in the CBS segment described in the report. The next step, after any formal submission to the Senate, would be the standard confirmation process for an FDA commissioner nominee, including potential hearings and committee consideration.
Why It Matters
- Early qualification assessments can shape how lawmakers and industry stakeholders approach confirmation questions about FDA leadership and regulatory priorities.
- For FDA oversight, leadership choices can influence how the agency sets policy direction across medical products, compliance, and evidence standards.
- If Overton advances through formal nomination steps, her “policy background” is likely to be a central focus in hearings and committee discussion.
- The practical effect of FDA leadership depends on confirmation timing and the scope of the Senate’s review, which were not detailed in the CBS segment.
Key Facts
- Former FDA Commissioner Dr. Scott Gottlieb told CBS News that President Donald Trump’s FDA pick, Dr. Heidi Overton, “could be a strong candidate.”
- Gottlieb said Overton’s potential strength is her “deep policy background.”
- CBS News reported the remarks in a “Face the Nation with Margaret Brennan” segment dated August 23, 2026.
- CBS described Gottlieb as serving on the boards of Pfizer and United Healthcare.
- The segment, as reported, did not provide further details on nomination timing, Senate committee scheduling, or specific FDA policy commitments from Overton.